CVS Health upgraded to Outperform from In Line at Evercore ISI

Evercore ISI upgraded CVS Health to Outperform from In Line with a price target of $83, up from $81. The analyst believes the company’s operational issues are improving while the stock’s current valuation is attractive. CVS, like many managed care companies, is a complex organization, but a number of factors are “swinging in a positive direction,” which brings a higher degree of confidence in management’s outlook as well as support for a higher valuation, the analyst tells investors in a research note.